Table 4.
Druggable fusions observed in cfDNA of the 25 GBM patients in this study. The different colours indicate the sources of the samples as listed under the same sample ID in Table 1.
| Biobank number | Observed fusions | Potential drugs |
|---|---|---|
| 100058 | BCR‐ABL | Imatinib, sunitinib and sorafenib |
| 100067 | KDR‐PDGFRA | Imatinib, sunitinib and sorafenib |
| 100077 | NCDN‐PDGFRA | Imatinib, sunitinib and sorafenib |
| 100156 | COL1A1‐PDGFB | Imatinib, sunitinib and sorafenib |
| 100101 | BCR‐ABL, KDR‐PDGFRA | Imatinib, sunitinib and sorafenib |
| 100106 | NA | NA |
| 100142 | NCDN‐PDGFRA | Imatinib, sunitinib and sorafenib |
| 100224 | FGFR1‐BCR | Imatinib, sunitinib and sorafenib |
| 100237 | CEP85L‐ROS1 | Crizotinib, entrectinib and larotrectinib |
| 100240 | NCDN‐PDGFRA | Imatinib, sunitinib and sorafenib |
| I | NCDN‐PDGFRA | Imatinib, sunitinib and sorafenib |
| II | GOPC‐ROS1 | Crizotinib, entrectinib and larotrectinib |
| IV | NIN‐PDGFRB | Imatinib, sunitinib and sorafenib |
| V | NA | NA |
| VIII | KDR‐PDGFRA | Imatinib, sunitinib and sorafenib |
| IX | NCDN‐PDGFRA | Imatinib, sunitinib and sorafenib |
| X | NA | NA |
| XI | COL1A1‐PDGFB, NCDN‐PDGFRA | Imatinib, sunitinib and sorafenib |
| XII | NIN‐PDGFRB | Imatinib, sunitinib and sorafenib |
| #1 | GOPC‐ROS1 | Crizotinib, entrectinib and larotrectinib |
| #3 | NCDN‐PDGFRA | Imatinib, sunitinib and sorafenib |
| #5 | NCDN‐PDGFRA | Imatinib, sunitinib and sorafenib |
| #7 | CEP85L‐ROS1 | Crizotinib, entrectinib and larotrectinib |
| #13 | NCDN‐PDGFRA | Imatinib, sunitinib and sorafenib |
| #33 | NCDN‐PDGFRA | Imatinib, sunitinib and sorafenib |